Edition:
United States

TherapeuticsMD Inc (TXMD.A)

TXMD.A on American Stock Exchange

6.06USD
25 Sep 2017
Change (% chg)

$-0.11 (-1.78%)
Prev Close
$6.17
Open
$6.12
Day's High
$6.21
Day's Low
$5.98
Volume
129,451
Avg. Vol
284,893
52-wk High
$8.29
52-wk Low
$3.50

Latest Key Developments (Source: Significant Developments)

Therapeuticsmd reports Q2 loss per share $0.11
Thursday, 4 Aug 2016 04:05pm EDT 

Therapeuticsmd Inc : Therapeuticsmd announces second quarter 2016 financial results . Q2 loss per share $0.11 . Q2 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S .Topline phase 3 data for tx-001hr replenish trial on track for q4 of 2016.  Full Article

TherapeuticsMD, Inc announces pricing of common stock offering
Thursday, 7 Jan 2016 06:45am EST 

TherapeuticsMD, Inc:Announces pricing of $125 million common stock offering.Says public offering priced at $8.25 per share.  Full Article

TherapeuticsMD Announces $125 Million Offering of Common Stock
Tuesday, 5 Jan 2016 04:00pm EST 

TherapeuticsMD, Inc:Says launch of an underwritten public offering of $125 million of shares of its common stock.expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock.All of the shares in the offering are to be sold by TherapeuticsMD.The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Goldman, Sachs & Co. and Cowen and Company are acting as joint bookrunning managers for the offering.Stifel is acting as joint lead manager for the offering and Guggenheim Securities is acting as co-manager for the offering.intends to use a majority of the proceeds of the offering to fund commercialization activities for TX-004HR, its applicator-free vaginal estradiol softgel drug candidate, for other research, clinical trials, clinical formulation and development and for working capital and general corporate purposes.  Full Article

TherapeuticsMD announces positive top-line results from its phase 3 rejoice trial in postmenopausal women with vulvar and vaginal atrophy (vva) treated with 25 mcg, 10 mcg or 4 mcg of tx-004hr
Monday, 7 Dec 2015 04:10pm EST 

TherapeuticsMD:Says positive top-line results from its pivotal Phase 3 Rejoice Trial of TX-004HR, an investigational, applicator-free vaginal estradiol softgel.Says this is for treatment of moderate to severe dyspareunia (vaginal pain during sexual intercourse), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.  Full Article

BRIEF-TherapeuticsMD announces public offering of 12.4 mln shares of common stock

* TherapeuticsMD announces public offering of 12.4 million shares of common stock Source text for Eikon: Further company coverage: